The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells

Cancer Letters

Volumn 281, Issue 2, 2009, Pages 171-182

  Kowalczyk, Aleksandra ^a   Gil, Małgorzata ^a   Horwacik, Irena ^a   Odrowaz, Zaneta ^a   Kozbor, Danuta ^b   Rokita, Hanna ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Chemoimmunotherapy; GD2 ganglioside; Monoclonal antibody; Neuroblastoma

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CARBOPLATIN; CASPASE 3; CHLOROQUINE; DOXORUBICIN; ETOPOSIDE; GANGLIOSIDE GD2; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14G2A; PROPIDIUM IODIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CELL ADHESION; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; MICROSCOPY, FLUORESCENCE; NEUROBLASTOMA; TOPOTECAN;

EID: 67349260735     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.040     Document Type: Article

References (56)

1. Nakagawara A., and Ohira M. Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. Cancer Lett. 204 (2004) 213-224
2. Maris J.M., and Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17 (1999) 2264-2279
3. Bordow S.B., Norris M.D., Haber P.S., Marshall G.M., and Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J. Clin. Oncol. 16 (1998) 3286-3294
4. Laverdiere C., Cheung N.K., Kushner B.H., Kramer K., Modak S., LaQuaglia M.P., Wolden S., Ness K.K., Gurney J.G., and Sklar C.A. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr. Blood Cancer 45 (2005) 324-332
5. Tonini G.P., and Pistoia V. Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr. Pharm. Design 12 (2006) 2303-2317
6. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res. 52 (1989) 257-331
7. Wu Z.L., Schwartz E., Seeger R., and Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 46 (1986) 440-443
8. Svennerholm L., Bostrom K., Fredman P., Jungbjer B., Lekman A., Mansson J.E., and Rynmark B.M. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1214 (1994) 115-123
9. Kowalczyk A., Wierzbicki A., Gil M., Bambach B., Kaneko Y., Rokita H., Repasky E., Fenstermaker R., Brecher M., Ciesielski M., and Kozbor D. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol. Immunother. 56 (2007) 1443-1458
10. Nakano J., Raj B.K., Asagami C., and Lloyd K.O. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J. Invest. Dermatol. 107 (1996) 543-548
11. Bjerkvig R., Engebraaten O., Laerum O.D., Fredman P., Svennerholm L., Vrionis F.D., Wikstrand C.J., and Bigner D.D. Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line. Cancer Res. 51 (1991) 4643-4648
12. Retter M.W., Johnson J.C., Peckham D.W., Bannink J.E., Bangur C.S., Dresser K., Cai F., Foy T.M., Fanger N.A., Fanger G.R., Woda B., and Rock K.L. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res. 65 (2005) 6425-6434
13. Aixinjueluo W., Furukawa K., Zhang Q., Hamamura K., Tokuda N., Yoshida S., and Ueda R. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem. 280 (2005) 29828-29836
14. Nakamura K., Hanibuchi M., Yano S., Tanaka Y., Fujino I., Inoue M., Takezawa T., Shitara K., Sone S., and Hanai N. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody. Cancer Res. 59 (1999) 5323-5330
15. Dippold W.G., Knuth A., and Meyer zum Buschenfelde K.H. Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 44 (1984) 806-810
16. Houghton A.N., Mintzer D., Cordon-Cardo C., Welt S., Fliegel B., Vadhan S., Carswell E., Melamed M.R., Oettgen H.F., and Old L.J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82 (1985) 1242-1246
17. Katano M., and Irie R.F. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice. Immunol. Lett. 8 (1984) 169-174
18. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M., Niethammer D., and Berthold F. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J. Clin. Oncol. 22 (2004) 3549-3557
19. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M., Niethammer D., and Berthold F. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin. Padiatr. 217 (2005) 147-152
20. Osenga K.L., Hank J.A., Albertini M.R., Gan J., Sternberg A.G., Eickhoff J., Seeger R.C., Matthay K.K., Reynolds C.P., Twist C., Krailo M., Adamson P.C., Reisfeld R.A., Gillies S.D., and Sondel P.M. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin. Cancer Res. 12 (2006) 1750-1759
21. Modak S., and Cheung N.K. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 25 (2007) 67-77
22. Yoshida S., Kawaguchi H., Sato S., Ueda R., and Furukawa K. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn. J. Cancer Res. 93 (2002) 816-824
23. Attard G., Kitzen J., Blagden S.P., Fong P.C., Pronk L.C., Zhi J., Zugmaier G., Verweij J., de Bono J.S., and de Jonge M. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Brit. J. Cancer 97 (2007) 1338-1343
24. Gallamini A., Zaja F., Patti C., Billio A., Specchia M.R., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., Pinto A., Iannitto E., Zoli V., Torchio P., Pileri S., and Tarella C. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110 (2007) 2316-2323
25. Tumilowicz J.J., Nichols W.W., Cholon J.J., and Greene A.E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res. 30 (1970) 2110-2118
26. Ruan S., Raj B.K., and Lloyd K.O. Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells. J. Neurochem. 72 (1999) 514-521
27. Karlsson J., Ora I., Porn-Ares I., and Pahlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin. Cancer. Res. 10 (2004) 3179-3188
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
29. Cheresh D.A., Pierschbacher M.D., Herzig M.A., and Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J. Cell Biol. 102 (1986) 688-696
30. Bouley R., Lin H.Y., Raychowdhury M.K., Marshansky V., Brown D., and Ausiello D.A. Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway. Am. J. Physiol. Cell Physiol. 288 (2005) C1390-C1401
31. Wargalla U.C., and Reisfeld R.A. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc. Natl. Acad. Sci. USA 86 (1989) 5146-5150
32. Rozzo C., Chiesa V., Caridi G., Pagnan G., and Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int. J. Cancer 70 (1997) 688-698
33. Kawaguchi Y., Kono K., Mimura K., Sugai H., Akaike H., and Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120 (2007) 781-787
34. Gorter A., and Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today 20 (1999) 576-582
35. Mujoo K., Kipps T.J., Yang H.M., Cheresh D.A., Wargalla U., Sander D.J., and Reisfeld R.A. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 49 (1989) 2857-2861
36. Alvarez-Rueda N., Leprieur S., Clemenceau B., Supiot S., Sebille-Rivain V., Faivre-Chauvet A., Davodeau F., Paris F., Barbet J., Aubry J., and Birkle S. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin. Cancer Res. 13 (2007) 5613s-5620s
37. Yoshida S., Fukumoto S., Kawaguchi H., Sato S., Ueda R., and Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61 (2001) 4244-4252
38. Boix J., Llecha N., Yuste V.J., and Comella J.X. Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines. Neuropharmacology 36 (1997) 811-821
39. Yuste V.J., Bayascas J.R., Llecha N., Sanchez-Lopez I., Boix J., and Comella J.X. The absence of oligonucleosomal DNA fragmentation during apoptosis of IMR-5 neuroblastoma cells: disappearance of the caspase-activated DNase. J. Biol. Chem. 276 (2001) 22323-22331
40. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., and Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20 (2001) 5865-5877
41. Cheresh D.A., and Klier F.G. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J. Cell Biol. 102 (1986) 1887-1897
42. Frisch S.M., and Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124 (1994) 619-626
43. Meyer A., van Golen C.M., Kim B., van Golen K.L., and Feldman E.L. Integrin expression regulates neuroblastoma attachment and migration. Neoplasia 6 (2004) 332-342
44. Dedhar S., and Gray V. Isolation of a novel integrin receptor mediating Arg-Gly-Asp-directed cell adhesion to fibronectin and type I collagen from human neuroblastoma cells. Association of a novel beta 1-related subunit with alpha v. J. Cell Biol. 110 (1990) 2185-2193
45. Han S., Khuri F.R., and Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 66 (2006) 315-323
46. Johnsen J.I., Segerstrom L., Orrego A., Elfman L., Henriksson M., Kagedal B., Eksborg S., Sveinbjornsson B., and Kogner P. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene (2007)
47. Cheng H.L., Steinway M., Delaney C.L., Franke T.F., and Feldman E.L. IGF-I promotes Schwann cell motility and survival via activation of Akt. Mol. Cell Endocrinol. 170 (2000) 211-215
48. Kidowaki T., Thiele C.J., Kleinman H.K., and Israel M.A. Matrix proteins induce neuroblastoma cell differentiation without altering cell growth. Pathobiology 59 (1991) 316-323
49. Kusano A., Ohta S., Shitara K., and Hanai N. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies. Anticancer Res. 13 (1993) 2207-2212
50. Hopkins-Donaldson S., Yan P., Bourloud K.B., Muhlethaler A., Bodmer J.L., and Gross N. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 21 (2002) 6132-6137
51. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., and Opipari Jr. A.W. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276 (2001) 48921-48929
52. Satoh T.H., Surmacz T.A., Nyormoi O., and Whitacre C.M. Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins. Biocell 27 (2003) 47-55
53. Nakashio A., Fujita N., Rokudai S., Sato S., and Tsuruo T. Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 60 (2000) 5303-5309
54. Floros K.V., Thomadaki H., Katsaros N., Talieri M., and Scorilas A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol. Chem. 385 (2004) 1099-1103
55. Itoh M., Chiba H., Noutomi T., Takada E., and Mizuguchi J. Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncol. 36 (2000) 277-285
56. Hodkinson P.S., Elliott T., Wong W.S., Rintoul R.C., Mackinnon A.C., Haslett C., and Sethi T. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13 (2006) 1776-1788